Scholarlink

Purpose <p>This study developed a coordinated-delivery phospholipid-based gel for therapeutics with distinct physicochemical properties to overcome the limitations of current monotherapies for gouty arthritis (GA), achieving synergistic therapeutic effects.</p> Methods <p>A phospholipid phase-transition gel (RMU-Gel) was prepared via a stirring method to co-encapsulate three agents with distinct physicochemical properties—resveratrol (Res), meloxicam (Melx), and uricase (URE). The study evaluated its <i>in vitro</i> release behavior, <i>in vivo</i> pharmacokinetics, the synergistic effects of Res and Melx, pharmacodynamics in a rat model of gouty arthritis, as well as the preliminary safety and biodegradability of the drug-loaded phospholipid gel.</p> Results <p><i>In vitro</i> release results showed that RMU-Gel enabled a slow and prolonged release of the drugs in the release medium. The combination of resveratrol and meloxicam significantly enhanced anti-inflammatory and antioxidant responses. In the rat model, a single dose of RMU-Gel provided therapeutic effects lasting over 7&#xa0;days, outperforming repeated injections of drug suspensions, with excellent safety and biodegradability.</p> Conclusion <p>RMU-Gel offers a simple yet powerful platform for the coordinated co-delivery of physicochemically diverse agents. Specifically, the major breakthrough of this study is the successful co-encapsulation and sustained co-release of three therapeutics with markedly different physicochemical properties within a single phospholipid gel system, thereby preserving their multi-pathway therapeutic synergy. This provides a promising multifunctional strategy for efficient management of gouty arthritis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Sustained Intra-Articular Delivery of Triple Therapeutics Using a Phase-Transition Phospholipid-Based Gel for Effective Treatment of Gouty Arthritis

  • 期刊论文

  • 发表日期：

    2026年6月30日

查看全文
  • Sirui Ma,
  • Jing Yang,
  • Ao Li,
  • Qing Lin,
  • Tao Gong

摘要

Purpose

This study developed a coordinated-delivery phospholipid-based gel for therapeutics with distinct physicochemical properties to overcome the limitations of current monotherapies for gouty arthritis (GA), achieving synergistic therapeutic effects.

Methods

A phospholipid phase-transition gel (RMU-Gel) was prepared via a stirring method to co-encapsulate three agents with distinct physicochemical properties—resveratrol (Res), meloxicam (Melx), and uricase (URE). The study evaluated its in vitro release behavior, in vivo pharmacokinetics, the synergistic effects of Res and Melx, pharmacodynamics in a rat model of gouty arthritis, as well as the preliminary safety and biodegradability of the drug-loaded phospholipid gel.

Results

In vitro release results showed that RMU-Gel enabled a slow and prolonged release of the drugs in the release medium. The combination of resveratrol and meloxicam significantly enhanced anti-inflammatory and antioxidant responses. In the rat model, a single dose of RMU-Gel provided therapeutic effects lasting over 7 days, outperforming repeated injections of drug suspensions, with excellent safety and biodegradability.

Conclusion

RMU-Gel offers a simple yet powerful platform for the coordinated co-delivery of physicochemically diverse agents. Specifically, the major breakthrough of this study is the successful co-encapsulation and sustained co-release of three therapeutics with markedly different physicochemical properties within a single phospholipid gel system, thereby preserving their multi-pathway therapeutic synergy. This provides a promising multifunctional strategy for efficient management of gouty arthritis.